OraSure Technologies, Inc. (NASDAQ:OSUR) Q1 2024 Earnings Conference Call May 8, 2024 4:45 PM ET Company Participants Jason Plagman – Vice President-Investor Relations Carrie Eglinton Manner – President and Chief Executive Officer Ken McGrath – Chief Financial Officer Conference Call Participants Jordan Adler – Evercore ISI Operator Good day, and thank you for standing by. Welcome to the OraSure Technologies First Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mod ...

OraSure Technologies (OSUR) came out with quarterly earnings of $0.04 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.37 per share a year ago. These figures are adjusted for non-recurring items.A quarter ago, it was expected that this diagnostic test maker would post earnings of $0.13 per share when it actually produced earnings of $0.22, delivering a surprise of 69.23%.Over the last four quarters, the company has surpassed consensus EPS estimates two times.OraSure, whi ...

EXHIBIT 99.1 Investor Contact: Media Contact: Jason Plagman Amy Koch VP, Investor Relations Director, Corporate Communications investorinfo@orasure.com media@orasure.com OraSure Reports Q1 ’24 Revenue of $54.1 Million Q1 GAAP EPS of $(0.05); Q1 Non-GAAP EPS of $0.04 Restructuring initiatives expected to result in $15 million of annualized expense reductions once fully implemented and position OraSure to achieve cash flow breakeven for core business by end of 2024 Delivered initial orders for Syphilis Health ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 __________________________________________________________ FORM 10-K __________________________________________________________ (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to Commission Fil ...

OraSure Technologies, Inc. (NASDAQ:OSUR) Q4 2023 Earnings Conference Call February 27, 2024 5:00 PM ET Company Participants Jason Plagman - Vice President-Investor Relations Carrie Eglinton Manner - President & Chief Executive Officer Ken McGrath - Chief Financial Officer Conference Call Participants Patrick Donnelly - Citi Jacob Johnson - Stephens Matthew Stanton - Jefferies Andrew Cooper - Raymond James Operator Good day, and thank you for standing by. Welcome to the OraSure Technologies Inc. 2023 Fourth ...

Investor Contact: Media Contact: Jason Plagman Amy Koch investorinfo@orasure.com media@orasure.com VP, Investor Relations Director, Corporate Communications OraSure Reports Q4 '23 Revenue of $75.9 Million Q4 GAAP EPS of $0.27; Q4 Non-GAAP EPS of $0.22 Grew cash balance to $290.4 million as of December 31, 2023 Enters U.S. Syphilis testing market via strategic distribution agreement with Diagnostics Direct BETHLEHEM, PA, February 27, 2024 (GLOBE NEWSWIRE) – OraSure Technologies, Inc. (NASDAQ: OSUR), a leader ...

OraSure Technologies, Inc. (NASDAQ:OSUR) Q3 2023 Earnings Conference Call November 7, 2023 5:00 PM ET Company Participants Jason Plagman - Vice President-Investor Relations Carrie Eglinton Manner - President & Chief Executive Officer Ken McGrath - Chief Financial Officer Conference Call Participants Jacob Johnson - Stephens Casey Woodring - JPMorgan Matt Stanton - Jefferies Andrew Cooper - Raymond James Operator Good day, and thank you for standing by. Welcome to the OraSure Technologies Inc 2023 Third Quar ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________________________ FORM 10-Q ______________________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023. OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________to _________ . Commission File Number 001-16537 ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________________________ FORM 10-Q ______________________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023. OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________to _________ . Commission File Number 001-16537 _____ ...

OraSure Technologies, Inc. (NASDAQ:OSUR) Q2 2023 Earnings Conference Call August 3, 2023 5:00 PM ET Company Participants Jason Plagman – Vice President-Investor Relations Carrie Eglinton Manner – President and Chief Executive Officer Ken McGrath – Chief Financial Officer Conference Call Participants Jacob Johnson – Stephens Operator Good day, and thank you for standing by. Welcome to the OraSure Technologies 2023 Second Quarter Earnings Conference Call. At this time all participants are in a listen-only mod ...